|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mettlin C, Lee F, Drago J and Murphy GP:
The American Cancer Society National Prostate Cancer Detection
Project. Histopathology. Cancer. 67:2949–58. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nadler RB, Humphrey PA, Smith DS, Catalona
WJ and Ratliff TL: Effect of inflammation and benign prostatic
hyperplasia on elevated serum prostate specific antigen levels. J
Urol. 154:407–413. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brawer MK: Prostate-specific antigen: C
urrent status. CA Cancer J Clin. 49:264–281. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gretzer MB and Partin AW: PSA markers in
prostate cancer detection. Urol Clin North Am. 30:677–686. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics biogenesis,
mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ha TY: MicroRNAs inH uman diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dews M, Homayouni A, Yu D, et al:
Augmentation of tumor angiogenesis by a Myc activated microRNA
cluster. Nat Genet. 38:1060–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayashita Y, Osada H, Tatematsu Y, et al:
A polycistronic microRNA cluster, miR-17-92, is overexpressed in
human lung cancers and enhances cell proliferation. Cancer Res.
65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao Y, Suo AL, Li ZF, et al: MicroRNA
profiling of human gastric cancer. Mol Med Rep. 2:963–970.
2009.PubMed/NCBI
|
|
15
|
de la Ayala Peña F, Kanasaki K, Kanasaki
M, Tangirala N, Maeda G and Kalluri R: Loss of p53 and acquisition
of angiogenic microRNA profile are insufficient to facilitate
progression of bladder urothelial carcinoma in situ to
invasive carcinoma. J Biol Chem. 286:20778–20787. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu TI, Hsu CH, Lee KH, et al:
MicroRNA-18a is elevated in prostate cancer and promotes
tumorigenesis through suppressing STK4 in vitro and in
vivo. Oncogenesis. 3:e992014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitchell PS, Parkin RK, Kroh EM, et al:
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kosaka N, Iguchi H, Yoshioka Y, Takeshita
F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular
transfer of microRNAs in living cells. J Biol Chem.
285:17442–17452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng H, Zhang L, Zhao Y, et al: Plasma
miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.
PLoS One. 8:e778532013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Ba Y, Ma L, et al:
Characterization of microRNAs in serum: A novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res. 18:997–1006.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang GK, Zhu JQ, Zhang JT, et al:
Circulating microRNA: A novel potential biomarker for early
diagnosis of acute myocardial infarction in humans. Eur Heart J.
31:659–666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roth P, Wischhusen J, Happold C, Chandran
PA, Hofer S, Eisele G, Weller M and Keller A: A specific miRNA
signature in the peripheral blood of glioblastoma patients. J
Neurochem. 118:449–457. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schrauder MG, Strick R, Schulz-Wendtland
R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A,
Hein A, et al: Circulating micro-RNAs as potential blood-based
markers for early stage breast cancer detection. PLoS One.
7:e297702012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meder B, Keller A, Vogel B, Haas J,
Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J,
Leidinger P, et al: MicroRNA signatures in total peripheral blood
as novel biomarkers for acute myocardial infarction. Basic Res
Cardiol. 106:13–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keller A, Leidinger P, Bauer A, Elsharawy
A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al:
Toward the blood-borne miRNome of human diseases. Nat Methods.
8:841–843. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Median-Villaamil V, Martinez-Breijo S,
Portela-Pereira P, Quindós-Varela M, Santamarina-Cainzos I,
Antón-Aparicio LM and Gómez-Veiga F: Circulating MicroRNAs in blood
of patients with prostate cancer. Actas Urol Esp. 38:633–639.
2014.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gleason DF and Mellinger GT: Prediction of
prognosis for prostatic adenocarcinoma by combined histological
grading and clinical staging. J Urol. 111:58–64. 1974.PubMed/NCBI
|
|
28
|
Gleason DF: Histologic grading of prostate
cancer: A perspective. Hum Pathol. 23:273–279. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sobin LH and Wittekind CH: TNM
Classification of Malignant Tumours (6th). New York, NY, USA:
Wiley-Liss. 184–187. 2002.
|
|
30
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Minoo P, Zlobec I, Baker K, Tornillo L,
Terracciano L, Jass JP and Lugli A: Prognostic significance of
mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol.
20:331–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou D, Conrad C, Xia F, Park J, Payer B,
Yin Y, Lauwers GY, Thasler W, Lee JT, Ayruch J and Bardeesy N: Mst1
and Mst2 maintain hepatocyte quiescence and suppress hepatocellular
carcinoma development through inactivation of the Yap1 oncogene.
Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morimura R, Komatsu S, Ichikawa D, et al:
Novel diagnostic value of circulating miR-18a in plasma of patients
with pancreatic cancer. Br J Cancer. 105:1733–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luo X, Stock C, Burwinkel B and Brenner H:
Identification and evaluation of plasma MicroRNAs for early
detection of colorectal cancer. PLoS One. 8:e628802013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hirajima S, Komatsu S, Ichikawa D,
Takeshita H, Konishi H, Shiozaki A, Morimura R, Tsujiura M, Nagata
H, Kawaguchi T, et al: Clinical impact of circulating miR-18a in
plasma of patients with oesophageal squamous cell carcinoma. Br J
Cancer. 108:1822–1829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoffman RM, Gilliland FD, Adams-Cameron M,
Hunt WC and Key CR: Prostate-specific antigen testing accuracy in
community practice. BMC Fam Pract. 3:192002. View Article : Google Scholar : PubMed/NCBI
|
